Journal
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK
Volume 14, Issue 7, Pages 882-913Publisher
HARBORSIDE PRESS
DOI: 10.6004/jnccn.2016.0093
Keywords
-
Categories
Funding
- Crucell
- NIH
- Janssen Pharmaceutical Products, LP
- Roche Laboratories, Inc.
- Merck Co., Inc.
- Rebiotix
- sanofi pasteur
- Astellas
- City of Hope
- Chimerix
- Gilead
- NeuralStem
- ViroPharma
- K-PAX Pharmaceuticals
- Allergan
- JMI Laboratories
- Ventrus
- Ansun
- HHS/ASPR
- NIAID Influenza Research Collaboration Social & Scientific Systems, Inc.
- Pfizer Inc.
- scynexis
- World Health Information Science Consultants
- GLG
Ask authors/readers for more resources
Infectious diseases are important causes of morbidity and mortality in patients with cancer. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Prevention and Treatment of Cancer-Related Infections characterize the major pathogens to which patients with cancer are susceptible, with a focus on the prevention, diagnosis, and treatment of major common and opportunistic infections. This portion of the guidelines highlights the sections on antifungal and antiviral prophylaxis. Antifungal and antiviral prophylaxis recommendations have expanded over the past few years. New agents for the treatment of fungal infections and incorporation of therapeutic drug monitoring are presented. Antiviral prophylaxis for hepatitis B and management considerations for hepatitis C and HIV have been further developed.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available